Aberdeen Group
WST icon

Aberdeen Group’s West Pharmaceutical WST Stock Holding History

Aberdeen Group’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22M Sell
61,351
-7,725
-11% -$2.36M 0.03% 414
2026
Q1 		$17.3M Buy
69,076
+3,448
+5% +$858K 0.03% 464
2025
Q4 		$18.1M Sell
65,628
-1,181
-2% -$323K 0.03% 465
2025
Q3 		$17.4M Buy
66,809
+951
+1% +$231K 0.03% 472
2025
Q2 		$14.4M Buy
65,858
+2,752
+4% +$588K 0.02% 505
2025
Q1 		$14M Sell
63,106
-106,834
-63% -$29.4M 0.03% 481
2024
Q4 		$55.6M Sell
169,940
-6,525
-4% -$2.05M 0.1% 193
2024
Q3 		$53.1M Sell
176,465
-11,626
-6% -$3.56M 0.1% 211
2024
Q2 		$62M Sell
188,091
-1,279
-0.7% -$452K 0.12% 177
2024
Q1 		$74.9M Buy
189,370
+7,313
+4% +$2.71M 0.15% 161
2023
Q4 		$64.1M Buy
182,057
+39,156
+27% +$13.9M 0.14% 165
2023
Q3 		$53.6M Sell
142,901
-238,243
-63% -$92.1M 0.14% 151
2023
Q2 		$146M Sell
381,144
-15,921
-4% -$5.69M 0.34% 69
2023
Q1 		$138M Sell
397,065
-11,101
-3% -$3.24M 0.34% 66
2022
Q4 		$96.1M Buy
408,166
+8,784
+2% +$2.08M 0.26% 89
2022
Q3 		$98.3M Buy
399,382
+96,232
+32% +$29.3M 0.29% 79
2022
Q2 		$91.1M Buy
303,150
+22,037
+8% +$7.17M 0.29% 81
2022
Q1 		$118M Buy
281,113
+12,775
+5% +$5M 0.3% 77
2021
Q4 		$126M Buy
268,338
+5,910
+2% +$2.54M 0.28% 87
2021
Q3 		$114M Sell
262,428
-3,239
-1% -$1.37M 0.26% 92
2021
Q2 		$95.4M Sell
265,667
-1,290
-0.5% -$426K 0.21% 102
2021
Q1 		$75.3M Sell
266,957
-2,877
-1% -$823K 0.17% 120
2020
Q4 		$76.4M Sell
269,834
-8,824
-3% -$2.48M 0.19% 119
2020
Q3 		$76.6M Buy
278,658
+5,066
+2% +$1.34M 0.2% 111
2020
Q2 		$62.2M Buy
273,592
+88,088
+47% +$17.3M 0.17% 118
2020
Q1 		$28.3M Buy
185,504
+178,123
+2,413% +$27.4M 0.09% 191
2019
Q4 		$1.11M Buy
+7,381
New +$1.07M ﹤0.01% 793

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Aberdeen Group's WST Position: Q2 2026 in Review

Aberdeen Group reduced its West Pharmaceutical (WST) stake by 11% in Q2 2026, selling an estimated $2.36M and leaving 61,351 shares worth $22M. The position accounts for 0.03% of the portfolio, ranked #414.

Aberdeen Group first reported a position in WST in Q4 2019 and has held it in 27 quarters since. The position peaked at $146M in Q2 2023. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Aberdeen Group held 61,351 shares of West Pharmaceutical worth $22M as of Q2 2026.
  • Aberdeen Group sold 7,725 West Pharmaceutical shares in Q2 2026, an estimated $2.36M.
  • West Pharmaceutical made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #414 holding.
  • Aberdeen Group first reported a position in West Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • Aberdeen Group's West Pharmaceutical position peaked at $146M in Q2 2023.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.